(via TheNewswire)

VANCOUVER, British Columbia – TheNewswire - December 4, 2025 - BetterLife Pharma Inc. (“BetterLife” or the “Compa ny”) ( CSE: BETR / OTCQB: BETRF / FRA: NPAU ) , an emerging biotech company, focused on development of BETR-001, its proprietary non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”).

Following recent news from a Phase 2 trial showing LSD microdosing is ineffective for depression, BetterLife highlights BETR-001's advantages over LSD. BETR-001 remains non-hallucinogenic even at high doses, as shown in our previous pu blication , and does not induce tolerance with repeated use, meaning that BETR-001 can be dosed on a chronic or repeated basis. Preclinical studies indicate that neuroplastogenic effects require sufficient dosing. Since BETR-001 can be administered at full dose without hallucinations, it maintains its effectiveness following repeated dosing.

Dr. Ahmad Doroudian, CEO of BetterLife, commented, “The importance of being able to give full doses of BETR-001 without hallucinations cannot be over-emphasized. Microdosing of psychedelics is often touted as the path forward to avoid the hallucinations of psychedelics full dosing and the need for treatment in specialized clinics with monitoring under special treatment protocols, which require in-clinic time of 8 to 12 hours. BETR-001 overcomes all these hurdles and can be administered at its full effective dose without any hallucinations.”

Dr. Doroudian further commented, “We are completing the last remaining BETR-001 IND-enabliing studies and plan to file the IND and begin human clinical trials by 2H 2026. Our initial scope is to develop BETR-001 for treatment of Traumatic Brain Injury (“TBI”), cluster headaches and migraine. BETR-001 also has potential for treatment of a broad range of psychiatric disorders and they will also be explored as the compound’s development life cycle moves forward.”

About BetterLife Pharma

BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing BETR-001 to treat various neurological disorders. BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered. BetterLife’s synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of various neurological disorders, until around 2042.

BetterLife also owns a drug candidate for the treatment of viral infections and is in the process of seeking strategic alternatives for further development.

For further information, please visit  BetterLife Pharma .

Contact

Ahmad Doroudian, Chief Executive Officer

Email:   Ahmad.Doroudian@blifepharma.com  

Phone: 1-604-221-0595

Cautionary Note Regarding Forward-Looking Statements

No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

Copyright (c) 2025 TheNewswire - All rights reserved.